Bladder Carcinoma — Trials

Bladder Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

332 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 141
Recruiting: 74
Ph III recruiting: 14
Growth YoY: +6.5%
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: 48.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (49)

clinicaltrialsPublishedShowing 1–10 of 10 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06211764	A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)(SunRISe-5)	active not recruiting	Phase 3	272	Janssen Research & Development, LLCINDUSTRY	14	Sep 25, 2026	clinicaltrials
NCT04579224	Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer	active not recruiting	Phase 3	184	National Cancer Institute (NCI)